$50 Million

Intra-Cellular

At-the-market Offering

Intra-Cellular Therapies is a biopharmaceutical company focused on the development of small molecule drugs that address neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder and other neuropsychiatric and neurological disorders.